The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Predictive Presymptomatic Testing Market Research Report 2025
Synopsis
The global Predictive Presymptomatic Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Predictive Presymptomatic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Predictive Presymptomatic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Predictive Presymptomatic Testing in Breast and Ovarian Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Predictive Presymptomatic Testing include 23andMe, Inc., Abbott Laboratories, Bayer HealthCare AG, Biocartis SA, BioHelix Corporation, bioMerieux S.A., Celera Corporation (Quest Diagnostics), Cepheid (Danaher) and Daan Diagnostics Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Predictive Presymptomatic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Predictive Presymptomatic Testing.
Report Scope
The Predictive Presymptomatic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Predictive Presymptomatic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Predictive Presymptomatic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
23andMe, Inc.
Abbott Laboratories
Bayer HealthCare AG
Biocartis SA
BioHelix Corporation
bioMerieux S.A.
Celera Corporation (Quest Diagnostics)
Cepheid (Danaher)
Daan Diagnostics Ltd.
EKF Diagnostics Holdings plc
Segment by Type
Molecular Testing
Cytogenic Testing
Biochemical Testing
Segment by Application
Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer's Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Predictive Presymptomatic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Predictive Presymptomatic Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Predictive Presymptomatic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Predictive Presymptomatic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Predictive Presymptomatic Testing in Breast and Ovarian Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Predictive Presymptomatic Testing include 23andMe, Inc., Abbott Laboratories, Bayer HealthCare AG, Biocartis SA, BioHelix Corporation, bioMerieux S.A., Celera Corporation (Quest Diagnostics), Cepheid (Danaher) and Daan Diagnostics Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Predictive Presymptomatic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Predictive Presymptomatic Testing.
Report Scope
The Predictive Presymptomatic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Predictive Presymptomatic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Predictive Presymptomatic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
23andMe, Inc.
Abbott Laboratories
Bayer HealthCare AG
Biocartis SA
BioHelix Corporation
bioMerieux S.A.
Celera Corporation (Quest Diagnostics)
Cepheid (Danaher)
Daan Diagnostics Ltd.
EKF Diagnostics Holdings plc
Segment by Type
Molecular Testing
Cytogenic Testing
Biochemical Testing
Segment by Application
Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer's Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Predictive Presymptomatic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Predictive Presymptomatic Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Molecular Testing
1.2.3 Cytogenic Testing
1.2.4 Biochemical Testing
1.3 Market by Application
1.3.1 Global Predictive Presymptomatic Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast and Ovarian Cancer
1.3.3 Colorectal Cancer
1.3.4 Alzheimer's Disease
1.3.5 Multiple Endocrine Neoplasia Type 2
1.3.6 Haemochromatosis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Predictive Presymptomatic Testing Market Perspective (2019-2030)
2.2 Predictive Presymptomatic Testing Growth Trends by Region
2.2.1 Global Predictive Presymptomatic Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Predictive Presymptomatic Testing Historic Market Size by Region (2019-2024)
2.2.3 Predictive Presymptomatic Testing Forecasted Market Size by Region (2025-2030)
2.3 Predictive Presymptomatic Testing Market Dynamics
2.3.1 Predictive Presymptomatic Testing Industry Trends
2.3.2 Predictive Presymptomatic Testing Market Drivers
2.3.3 Predictive Presymptomatic Testing Market Challenges
2.3.4 Predictive Presymptomatic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Predictive Presymptomatic Testing Players by Revenue
3.1.1 Global Top Predictive Presymptomatic Testing Players by Revenue (2019-2024)
3.1.2 Global Predictive Presymptomatic Testing Revenue Market Share by Players (2019-2024)
3.2 Global Predictive Presymptomatic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Predictive Presymptomatic Testing Revenue
3.4 Global Predictive Presymptomatic Testing Market Concentration Ratio
3.4.1 Global Predictive Presymptomatic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Predictive Presymptomatic Testing Revenue in 2023
3.5 Predictive Presymptomatic Testing Key Players Head office and Area Served
3.6 Key Players Predictive Presymptomatic Testing Product Solution and Service
3.7 Date of Enter into Predictive Presymptomatic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Predictive Presymptomatic Testing Breakdown Data by Type
4.1 Global Predictive Presymptomatic Testing Historic Market Size by Type (2019-2024)
4.2 Global Predictive Presymptomatic Testing Forecasted Market Size by Type (2025-2030)
5 Predictive Presymptomatic Testing Breakdown Data by Application
5.1 Global Predictive Presymptomatic Testing Historic Market Size by Application (2019-2024)
5.2 Global Predictive Presymptomatic Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Predictive Presymptomatic Testing Market Size (2019-2030)
6.2 North America Predictive Presymptomatic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Predictive Presymptomatic Testing Market Size by Country (2019-2024)
6.4 North America Predictive Presymptomatic Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Predictive Presymptomatic Testing Market Size (2019-2030)
7.2 Europe Predictive Presymptomatic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Predictive Presymptomatic Testing Market Size by Country (2019-2024)
7.4 Europe Predictive Presymptomatic Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Predictive Presymptomatic Testing Market Size (2019-2030)
8.2 Asia-Pacific Predictive Presymptomatic Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Predictive Presymptomatic Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Predictive Presymptomatic Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Predictive Presymptomatic Testing Market Size (2019-2030)
9.2 Latin America Predictive Presymptomatic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Predictive Presymptomatic Testing Market Size by Country (2019-2024)
9.4 Latin America Predictive Presymptomatic Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Predictive Presymptomatic Testing Market Size (2019-2030)
10.2 Middle East & Africa Predictive Presymptomatic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Predictive Presymptomatic Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Predictive Presymptomatic Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 23andMe, Inc.
11.1.1 23andMe, Inc. Company Detail
11.1.2 23andMe, Inc. Business Overview
11.1.3 23andMe, Inc. Predictive Presymptomatic Testing Introduction
11.1.4 23andMe, Inc. Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.1.5 23andMe, Inc. Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Detail
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Predictive Presymptomatic Testing Introduction
11.2.4 Abbott Laboratories Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.2.5 Abbott Laboratories Recent Development
11.3 Bayer HealthCare AG
11.3.1 Bayer HealthCare AG Company Detail
11.3.2 Bayer HealthCare AG Business Overview
11.3.3 Bayer HealthCare AG Predictive Presymptomatic Testing Introduction
11.3.4 Bayer HealthCare AG Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.3.5 Bayer HealthCare AG Recent Development
11.4 Biocartis SA
11.4.1 Biocartis SA Company Detail
11.4.2 Biocartis SA Business Overview
11.4.3 Biocartis SA Predictive Presymptomatic Testing Introduction
11.4.4 Biocartis SA Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.4.5 Biocartis SA Recent Development
11.5 BioHelix Corporation
11.5.1 BioHelix Corporation Company Detail
11.5.2 BioHelix Corporation Business Overview
11.5.3 BioHelix Corporation Predictive Presymptomatic Testing Introduction
11.5.4 BioHelix Corporation Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.5.5 BioHelix Corporation Recent Development
11.6 bioMerieux S.A.
11.6.1 bioMerieux S.A. Company Detail
11.6.2 bioMerieux S.A. Business Overview
11.6.3 bioMerieux S.A. Predictive Presymptomatic Testing Introduction
11.6.4 bioMerieux S.A. Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.6.5 bioMerieux S.A. Recent Development
11.7 Celera Corporation (Quest Diagnostics)
11.7.1 Celera Corporation (Quest Diagnostics) Company Detail
11.7.2 Celera Corporation (Quest Diagnostics) Business Overview
11.7.3 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Introduction
11.7.4 Celera Corporation (Quest Diagnostics) Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.7.5 Celera Corporation (Quest Diagnostics) Recent Development
11.8 Cepheid (Danaher)
11.8.1 Cepheid (Danaher) Company Detail
11.8.2 Cepheid (Danaher) Business Overview
11.8.3 Cepheid (Danaher) Predictive Presymptomatic Testing Introduction
11.8.4 Cepheid (Danaher) Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.8.5 Cepheid (Danaher) Recent Development
11.9 Daan Diagnostics Ltd.
11.9.1 Daan Diagnostics Ltd. Company Detail
11.9.2 Daan Diagnostics Ltd. Business Overview
11.9.3 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Introduction
11.9.4 Daan Diagnostics Ltd. Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.9.5 Daan Diagnostics Ltd. Recent Development
11.10 EKF Diagnostics Holdings plc
11.10.1 EKF Diagnostics Holdings plc Company Detail
11.10.2 EKF Diagnostics Holdings plc Business Overview
11.10.3 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Introduction
11.10.4 EKF Diagnostics Holdings plc Revenue in Predictive Presymptomatic Testing Business (2019-2024)
11.10.5 EKF Diagnostics Holdings plc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Predictive Presymptomatic Testing Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Molecular Testing
Table 3. Key Players of Cytogenic Testing
Table 4. Key Players of Biochemical Testing
Table 5. Global Predictive Presymptomatic Testing Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Predictive Presymptomatic Testing Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Predictive Presymptomatic Testing Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Predictive Presymptomatic Testing Market Share by Region (2019-2024)
Table 9. Global Predictive Presymptomatic Testing Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Predictive Presymptomatic Testing Market Share by Region (2025-2030)
Table 11. Predictive Presymptomatic Testing Market Trends
Table 12. Predictive Presymptomatic Testing Market Drivers
Table 13. Predictive Presymptomatic Testing Market Challenges
Table 14. Predictive Presymptomatic Testing Market Restraints
Table 15. Global Predictive Presymptomatic Testing Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Predictive Presymptomatic Testing Market Share by Players (2019-2024)
Table 17. Global Top Predictive Presymptomatic Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Predictive Presymptomatic Testing as of 2023)
Table 18. Ranking of Global Top Predictive Presymptomatic Testing Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Predictive Presymptomatic Testing Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Predictive Presymptomatic Testing Product Solution and Service
Table 22. Date of Enter into Predictive Presymptomatic Testing Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Predictive Presymptomatic Testing Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Predictive Presymptomatic Testing Revenue Market Share by Type (2019-2024)
Table 26. Global Predictive Presymptomatic Testing Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Predictive Presymptomatic Testing Revenue Market Share by Type (2025-2030)
Table 28. Global Predictive Presymptomatic Testing Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Predictive Presymptomatic Testing Revenue Market Share by Application (2019-2024)
Table 30. Global Predictive Presymptomatic Testing Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Predictive Presymptomatic Testing Revenue Market Share by Application (2025-2030)
Table 32. North America Predictive Presymptomatic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Predictive Presymptomatic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Predictive Presymptomatic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Predictive Presymptomatic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Predictive Presymptomatic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Predictive Presymptomatic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Predictive Presymptomatic Testing Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Predictive Presymptomatic Testing Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Predictive Presymptomatic Testing Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Predictive Presymptomatic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Predictive Presymptomatic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Predictive Presymptomatic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Predictive Presymptomatic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Predictive Presymptomatic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Predictive Presymptomatic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 47. 23andMe, Inc. Company Detail
Table 48. 23andMe, Inc. Business Overview
Table 49. 23andMe, Inc. Predictive Presymptomatic Testing Product
Table 50. 23andMe, Inc. Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 51. 23andMe, Inc. Recent Development
Table 52. Abbott Laboratories Company Detail
Table 53. Abbott Laboratories Business Overview
Table 54. Abbott Laboratories Predictive Presymptomatic Testing Product
Table 55. Abbott Laboratories Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 56. Abbott Laboratories Recent Development
Table 57. Bayer HealthCare AG Company Detail
Table 58. Bayer HealthCare AG Business Overview
Table 59. Bayer HealthCare AG Predictive Presymptomatic Testing Product
Table 60. Bayer HealthCare AG Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 61. Bayer HealthCare AG Recent Development
Table 62. Biocartis SA Company Detail
Table 63. Biocartis SA Business Overview
Table 64. Biocartis SA Predictive Presymptomatic Testing Product
Table 65. Biocartis SA Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 66. Biocartis SA Recent Development
Table 67. BioHelix Corporation Company Detail
Table 68. BioHelix Corporation Business Overview
Table 69. BioHelix Corporation Predictive Presymptomatic Testing Product
Table 70. BioHelix Corporation Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 71. BioHelix Corporation Recent Development
Table 72. bioMerieux S.A. Company Detail
Table 73. bioMerieux S.A. Business Overview
Table 74. bioMerieux S.A. Predictive Presymptomatic Testing Product
Table 75. bioMerieux S.A. Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 76. bioMerieux S.A. Recent Development
Table 77. Celera Corporation (Quest Diagnostics) Company Detail
Table 78. Celera Corporation (Quest Diagnostics) Business Overview
Table 79. Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Product
Table 80. Celera Corporation (Quest Diagnostics) Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 81. Celera Corporation (Quest Diagnostics) Recent Development
Table 82. Cepheid (Danaher) Company Detail
Table 83. Cepheid (Danaher) Business Overview
Table 84. Cepheid (Danaher) Predictive Presymptomatic Testing Product
Table 85. Cepheid (Danaher) Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 86. Cepheid (Danaher) Recent Development
Table 87. Daan Diagnostics Ltd. Company Detail
Table 88. Daan Diagnostics Ltd. Business Overview
Table 89. Daan Diagnostics Ltd. Predictive Presymptomatic Testing Product
Table 90. Daan Diagnostics Ltd. Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 91. Daan Diagnostics Ltd. Recent Development
Table 92. EKF Diagnostics Holdings plc Company Detail
Table 93. EKF Diagnostics Holdings plc Business Overview
Table 94. EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Product
Table 95. EKF Diagnostics Holdings plc Revenue in Predictive Presymptomatic Testing Business (2019-2024) & (US$ Million)
Table 96. EKF Diagnostics Holdings plc Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Predictive Presymptomatic Testing Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Predictive Presymptomatic Testing Market Share by Type: 2023 VS 2030
Figure 3. Molecular Testing Features
Figure 4. Cytogenic Testing Features
Figure 5. Biochemical Testing Features
Figure 6. Global Predictive Presymptomatic Testing Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Predictive Presymptomatic Testing Market Share by Application: 2023 VS 2030
Figure 8. Breast and Ovarian Cancer Case Studies
Figure 9. Colorectal Cancer Case Studies
Figure 10. Alzheimer's Disease Case Studies
Figure 11. Multiple Endocrine Neoplasia Type 2 Case Studies
Figure 12. Haemochromatosis Case Studies
Figure 13. Predictive Presymptomatic Testing Report Years Considered
Figure 14. Global Predictive Presymptomatic Testing Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Predictive Presymptomatic Testing Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Predictive Presymptomatic Testing Market Share by Region: 2023 VS 2030
Figure 17. Global Predictive Presymptomatic Testing Market Share by Players in 2023
Figure 18. Global Top Predictive Presymptomatic Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Predictive Presymptomatic Testing as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Predictive Presymptomatic Testing Revenue in 2023
Figure 20. North America Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Predictive Presymptomatic Testing Market Share by Country (2019-2030)
Figure 22. United States Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Predictive Presymptomatic Testing Market Share by Country (2019-2030)
Figure 26. Germany Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Predictive Presymptomatic Testing Market Share by Region (2019-2030)
Figure 34. China Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Predictive Presymptomatic Testing Market Share by Country (2019-2030)
Figure 42. Mexico Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Predictive Presymptomatic Testing Market Share by Country (2019-2030)
Figure 46. Turkey Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Predictive Presymptomatic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. 23andMe, Inc. Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 49. Abbott Laboratories Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 50. Bayer HealthCare AG Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 51. Biocartis SA Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 52. BioHelix Corporation Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 53. bioMerieux S.A. Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 54. Celera Corporation (Quest Diagnostics) Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 55. Cepheid (Danaher) Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 56. Daan Diagnostics Ltd. Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 57. EKF Diagnostics Holdings plc Revenue Growth Rate in Predictive Presymptomatic Testing Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
